Move Over, Pot: Psychedelic Companies Are About to Go Public
- Trials test whether the drugs can treat depression, addiction
- Mind Medicine plans to list on Toronto’s NEO Exchange in March
This article is for subscribers only.
The first companies developing medical treatments from psychedelic drugs like LSD, ketamine and the active ingredient in magic mushrooms are gearing up to list on Canadian stock exchanges.
Mind Medicine Inc., which is undertaking clinical trials of psychedelic-based drugs, intends to list on Toronto’s NEO Exchange by the first week of March, said JR Rahn, the company’s co-founder and co-chief executive officer. A NEO spokesman confirmed the listing, which is pending final approvals.